Procalcitonin (PCT) Assay Market

Procalcitonin (PCT) Assay Market Size, Market Forecast and Outlook By FMI

The procalcitonin (pct) assay market was valued at USD 316.4 million in 2025. The market is set to reach USD 336.0 million by 2026-end and grow at a CAGR of 6.2% between 2026-2036 to reach USD 613.2 million by 2036. Serum will dominate with a 34.2% share, while Test Kits (Procalcitonin ELISA Test Kits, Procalcitonin CLIA Kits, PCT Immunochromatography Kits, PCT Rapid Test Kits) will lead with a 68.7% share.

Summary of the Procalcitonin (PCT) Assay Market

• Demand and Growth Drivers
  • Demand for procalcitonin (pct) assay market products is shaped by evolving end-user requirements and procurement cycle shifts across primary application areas.
  • Regulatory and compliance developments are creating structured adoption pathways, particularly in high-growth regions.
  • Cost optimization priorities and operational efficiency requirements are sustaining replacement and upgrade cycles across end-use industries.
• Product and Segment View
  • The serum segment is expected to hold 34.2% of the sample type segment in 2026, as demand remains stable across core application areas.
  • By Product, Test Kits (Procalcitonin Elisa Test Kits, Procalcitonin Clia Kits, Pct Immunochromatography Kits, Pct Rapid Test Kits) is Expected to Account for the Largest Share of the Global Procalcitonin Testing Market in 2020.
  • Hospitals lead the end-use category with 36.7%, owing to procurement structures and institutional demand patterns.
• Geography and Competitive Outlook
  • China is expected to lead growth at 6.7% CAGR through 2036, driven by structural demand and investment expansion.
  • Germany follows at 6.6%, driven by structural demand and investment expansion.
  • Thermo Fisher Scientific Inc., Roche Diagnostics, bioMérieux SA are among the leading companies, competing on product breadth, regulatory approvals, and institutional procurement relationships.
• Analyst Opinion
  • 'The procalcitonin (pct) assay market is evolving structurally, with companies that can combine cost efficiency and application-specific performance gaining share,' says Sabyasachi Ghosh, Principal Consultant at FMI.
  • Growth at 6.2% CAGR is supported by sustained end-user demand and expanding geographic coverage.
  • Companies with integrated supply chains and established distribution networks are positioned to capture the majority of incremental demand.
  • Product differentiation and compliance capabilities are emerging as key competitive factors across growth markets.

Key Takeaways, Market Size, and Forecast

• The procalcitonin (pct) assay market was valued at USD 316.40 million in 2025.
• By 2036, the Procalcitonin (PCT) Assay Market is expected to be worth USD 613.21 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 6.2%.
• The market is projected to create an incremental opportunity of USD 277.19 million between 2026 and 2036.
• In 2026, Serum is expected to account for 34.2% of the sample type segment, driven by clinical adoption and regulatory compliance requirements.
• China (6.7%) and Germany (6.6%) are two of the fastest growing markets in the world.

Procalcitonin (PCT) Assay Market Definition

The procalcitonin (pct) assay market encompasses all commercially relevant products and services within the defined market boundary, covering primary product categories, application areas, and distribution channels active during the forecast period.

Procalcitonin (PCT) Assay Market Inclusions

Market scope covers all commercially available products within the defined taxonomy, segmented by the primary classification dimensions identified in the report. Revenue scope spans from 2026 to 2036.

Procalcitonin (PCT) Assay Market Exclusions

The scope does not include products or services outside the defined market boundary, including adjacent categories that fall under separate market definitions.

Procalcitonin (PCT) Assay Market Research Methodology

• Primary Research: FMI analysts spoke to industry participants, product specialists and regional distributors in key markets.
• Desk Research: Combination of data from industry associations, regulatory filings, sustainability certifications and manufacturer reports.
• Market sizing and forecasting - bottom-up aggregation by segment and geography, triangulated with top-down industry benchmarks and adoption curves.
• Data Validation: Quarterly cross-checks against industry production data, manufacturer disclosures and trade statistics.

Why is the Procalcitonin (PCT) Assay Market Growing?

• The demand is driven by changes in end user needs and shifts in procurement cycle.
• Regulatory developments are creating structured adoption paths.
• Replacement and upgrade cycles are being supported by cost optimization priorities.

The procalcitonin (pct) assay market is set to grow at 6.2% through 2036.

The concentration of segments indicates the existing trends of commercial demand.

Geographic expansion is spread across core markets.

Market Segmentation Analysis

• Serum accounts for 34.2% of sample type demand in 2026, maintaining its position as the primary procalcitonin (pct) assay market category.
• By product, test kits (procalcitonin elisa test kits, procalcitonin clia kits, pct immunochromatography kits, pct rapid test kits) leads at 68.7% share, reflecting concentrated demand in the primary use case.
• Hospital holds 36.7% of end-use demand, indicating the dominant channel or format preference.

The procalcitonin (pct) assay market is segmented on the basis of sample type, product, end-use, purpose. Serum is the most occurrence sample type in 2026 accounting for 34.2% share. Segment structures are a representation of the current procurement patterns and end-user preferences in the application areas.

Insights into the Serum Sample Type Segment

Serum accounts for undefined demand in sample type in 2026. This concentration is consistent with current procurement trends and end-user needs in the primary application category. Secondary segments address specialized needs and niche applications.

Insights into the Test Kits (Procalcitonin ELISA Test Kits, Procalcitonin CLIA Kits, PCT Immunochromatography Kits, PCT Rapid Test Kits) Product Segment

Test Kits (Procalcitonin ELISA Test Kits, Procalcitonin CLIA Kits, PCT Immunochromatography Kits, PCT Rapid Test Kits) accounts for undefined of product demand in 2026. This concentration reflects established procurement patterns and end user requirements within the primary application category. Secondary segments address specific needs and niche applications.

Procalcitonin (PCT) Assay Market Drivers, Restraints, and Opportunities

• Aging population and prevalence of chronic diseases are supported procurement demand for procalcitonin (pct) assay market products in hospitals, ambulatory care, and home healthcare settings.
• Barriers to entry include the regulatory approval processes and the need to generate clinical evidence which leads to market share being concentrated among established companies with approved product portfolios.
• Outpatient and home care shift is opening up new growth avenues and product format needs outside of traditional institutional procurement.

The market for the procalcitonin (pct) assay is influenced by patient demographics, clinical protocols and the purchasing habits of institutions. Growth is non-discretionary, driven by clinical need and supported by healthcare spend that is robust through economic cycles.

Demographic and Disease Prevalence Drivers

Demand is driven by aging populations and an increasing prevalence of chronic conditions requiring ongoing clinical management and product consumption. Serum leads with 34.2% share underpinned by established clinical preference and evidence-based uptake. This creates predictable revenue streams based on recurring consumption patterns and replacement.

Regulatory and Clinical Evidence Barriers

Regulatory approval processes, clinical trial requirements and hospital formulary inclusion criteria impede adoption of new products. Established manufacturers with clinical evidence and regulatory clearances have a competitive advantage. New entrants face multi-year regulatory approval and clinical adoption timelines.

Institutional Procurement and Formulary Access

Market access is dependent on inclusion in the hospital formulary, contracts with group purchasing organizations (GPOs) and institutional procurement relationships. Hospitals also have deep purchasing budgets, which is good for suppliers with broad product portfolios, reliable supply and good volume pricing through long-term supply agreements.

Care Setting Expansion and Format Innovation

The growth is fueled by the expansion of care delivery from the hospital inpatient setting to ambulatory centers, outpatient clinics and home healthcare. This necessitates adapted product formats, straightforward instructions and distribution models that function in fragmented, lower volume buying situations.

Analysis of Procalcitonin (PCT) Assay Market By Key Countries

Country	CAGR
China	6.7%
Germany	6.6%
USA	6.5%
South Korea	6.4%
France	6.3%
Italy	6.0%
UK	5.8%
Australia	5.7%
Japan	5.6%
New Zealand	5.3%

Source: FMI analysis based on primary research and proprietary forecasting model

• China at 6.7% leads growth through 2036, driven by structural demand and investment expansion.
• Germany at 6.6% sustains growth through 2036, driven by structural demand and investment expansion.
• USA at 6.5% sustains growth through 2036, driven by structural demand and investment expansion.
• South Korea at 6.4% sustains growth through 2036, driven by structural demand and investment expansion.

The global procalcitonin (pct) assay market is projected to expand at 6.2% from 2026 to 2036. The analysis covers key markets across major regions, with country-level growth rates reflecting structural demand differences, regulatory environments, and investment patterns.

Demand Outlook for Procalcitonin (PCT) Assay Market in China

China is expected to be the fastest growing market at 6.7% through 2036, with growth driven by hospital laboratory modernization in both Tier 1 and Tier 2 systems, expanding ICU capacity leading to the need for sepsis biomarker testing, and government antibiotic stewardship programs to reduce the development of antimicrobial resistance. Serum based PCT testing is the leading sample type demand with 34.2%.

• Hospital lab modernization drives PCT assay platform acquisition.
• Demand for sepsis biomarker testing from ICU capacity expansion .
• Differentiation of bacterial infections for government antibiotic stewardship programs.

Future Outlook for Procalcitonin (PCT) Assay Market in Germany

Germany is expected to grow at 6.6% until 2036 due to early introduction of PCT-guided antibiotic therapy protocols, strong infrastructure of ICU laboratories and inclusion of PCT testing in clinical guidelines for sepsis management by the German Sepsis Society recommendations.

• Early implementation of the PCT protocol builds a clinical practice base.
• ICU laboratory infrastructure facilitates high-volume PCT testing
• Systematic PCT ordering based on integration of sepsis management guidelines .

Opportunity Analysis of Procalcitonin (PCT) Assay Market in USA

USA growth through 2036 will be fueled by CMS reimbursement for PCT-guided antibiotic decision-making, SEP-1 sepsis bundle compliance requirements driving systematic biomarker testing, and increased use of emergency departments for respiratory infection triage and antibiotic start decisions (6.5% CAGR).

• Institutional purchasing of PCT testing platforms supported by CMS reimbursement.
• Compliance with the SEP-1 sepsis bundle drives systematic PCT ordering in the hospital.
• Triage in the emergency department means testing beyond ICU.

In-depth Analysis of Procalcitonin (PCT) Assay Market in South Korea

South Korea’s growth is projected at 6.4% during the forecast period through 2036, driven by investment in hospital infection control due to increased awareness following the pandemic, modernization of diagnostic protocols in ICUs, and Korean CDC guidelines to supplement biomarker-guided antibiotic prescribing in hospital settings.

• Hospital infection control drives diagnostic platform procurement.
• ICU protocol upgrade supports PCT testing integration
• Korean CDC antibiotic guidelines-supported biomarker-guided prescribing.

Sales Analysis of Procalcitonin (PCT) Assay Market in France

France is projected to grow at 6.3% through 2036, reflecting integration of PCT testing into French critical care guidelines, hospital laboratory automation investment, and antibiotic stewardship programs aligned with European Antibiotic Awareness Day objectives.

• French critical care guidelines integrate PCT-guided antibiotic decisions.
• Hospital laboratory automation supports efficient PCT testing workflows.
• Antibiotic stewardship programs sustain systematic PCT ordering.

Growth Analysis of Procalcitonin (PCT) Assay Market in Italy

Italy is expected to grow at 6.0% through 2036, driven by ICU capacity investment in northern hospital systems, growing adoption of sepsis biomarker testing protocols, and antibiotic stewardship programs responding to high regional antimicrobial resistance rates.

• ICU capacity investment in northern hospitals drives PCT platform procurement.
• Sepsis biomarker protocol adoption expands PCT testing volumes.
• High antimicrobial resistance rates sustain antibiotic stewardship investment.

Market Assessment of Procalcitonin (PCT) Assay Market in UK

The UK is projected to grow at 5.8% through 2036, supported by NICE diagnostic assessment guidance on PCT testing, NHS antimicrobial stewardship programs, and growing adoption in emergency medicine for differentiating bacterial from viral lower respiratory tract infections.

• NICE diagnostic guidance supports evidence-based PCT testing adoption.
• NHS antimicrobial stewardship programs drive systematic PCT ordering.
• Emergency medicine adoption expands testing beyond critical care.

Strategic Outlook for Procalcitonin (PCT) Assay Market in Australia

Australia is expected to grow at 5.7% through 2036, reflecting integration of PCT testing into Australian sepsis clinical pathways, hospital laboratory modernization, and antimicrobial stewardship programs aligned with ACSQHC guidelines for responsible antibiotic prescribing.

• Sepsis clinical pathway integration drives PCT testing adoption.
• Hospital laboratory modernization supports platform procurement.
• ACSQHC antimicrobial stewardship guidelines sustain systematic testing.

Demand Assessment of Procalcitonin (PCT) Assay Market in Japan

Japan is projected to grow at 5.6% through 2036, supported by ICU laboratory infrastructure, Japanese Society of Intensive Care Medicine guideline recommendations, and growing clinical recognition of PCT's value in differentiating bacterial sepsis from systemic inflammatory conditions.

• ICU laboratory infrastructure supports high-quality PCT testing capability.
• JSICM guideline recommendations drive clinical adoption.
• Clinical recognition of PCT diagnostic value expands ordering patterns.

Performance Analysis of Procalcitonin (PCT) Assay Market in New Zealand

New Zealand is expected to grow at 5.3% through 2036, driven by hospital laboratory capacity, antimicrobial stewardship programs, and clinical adoption of PCT testing aligned with Australian clinical practice patterns.

• Hospital laboratory capacity supports PCT testing integration.
• Antimicrobial stewardship programs sustain systematic biomarker ordering.
• Clinical alignment with Australian practice supports protocol adoption.

Competitive Landscape and Strategic Positioning

• Thermo Fisher Scientific Inc. possesses a strong market position and product breadth, backed by a well established distribution and customer relationships.
• Roche Diagnostics, bioMérieux SA and Siemens Healthineers AG are well-positioned based on product breadth, clinical evidence and institutional procurement relationships.
• Emerging players are targeting niche device segments, AI-enabled diagnostics and affordable alternatives, to establish their presence in the market.

The competitive landscape is characterized by product breadth, geographic coverage and customer relationships.

The top players have the size and the well-developed distribution channels to hold their positions

Barriers to entry: Capital requirements, regulatory compliance, customer access

Key Companies in the Procalcitonin (PCT) Assay Market

Key global companies leading the procalcitonin (pct) assay market include:

• Thermo Fisher Scientific Inc., Roche Diagnostics, bioMérieux SA, Siemens Healthineers AG maintain leading positions through product breadth, established distribution networks, and scale advantages.
• Danaher Corporation (Beckman Coulter), Boditech Med Inc., DiaSorin S.p.A. serve regional and specialized market segments with focused product portfolios.
• Vazyme Biotech Co., Ltd., Sichuan Maccura Biotechnology Co., Ltd., Wondfo Biotech Co., Ltd., DRG Instruments GmbH, Abbott Laboratories, Snibe Diagnostic are emerging players focusing on specialized capabilities and niche market opportunities.

Competitive Benchmarking: Procalcitonin (PCT) Assay Market

Company	Product Range	Market Reach	Technology	Customer Access
Thermo Fisher Scientific Inc.	High	High	Medium	Medium
Roche Diagnostics	High	High	Medium	Medium
bioMérieux SA	High	High	Medium	Medium
Siemens Healthineers AG	High	High	Medium	Medium
Danaher Corporation (Beckman Coulter)	High	High	Medium	Medium
Boditech Med Inc.	High	High	Medium	Medium
DiaSorin S.p.A.	High	High	Medium	Medium
Vazyme Biotech Co., Ltd.	High	High	Medium	Medium
Sichuan Maccura Biotechnology Co., Ltd.	High	High	Medium	Medium
Wondfo Biotech Co., Ltd.	High	High	Medium	Medium

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Procalcitonin (PCT) Assay Market

• In 2025, DiaSys Diagnostic Systems GmbH expanded its clinical infection diagnostics portfolio by securing USA FDA 510(k) clearance for its Procalcitonin FS Assay, along with dedicated calibrators and control materials, supporting automated and precise testing for early sepsis risk assessment in clinical laboratories.
• In 2025, leading diagnostic companies strengthened their high-throughput immunoassay portfolios through broader clinical adoption of advanced procalcitonin (PCT) assay platforms, including chemiluminescent microparticle immunoassay (CMIA) and TRACE-based technologies, supporting faster sepsis detection in emergency and critical care settings.

Key Players in the Procalcitonin (PCT) Assay Market

Major Global Players

• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• bioMérieux SA
• Siemens Healthineers AG
• Danaher Corporation (Beckman Coulter)
• Boditech Med Inc.
• DiaSorin S.p.A.

Emerging Players/Startups

• Vazyme Biotech Co., Ltd.
• Sichuan Maccura Biotechnology Co., Ltd.
• Wondfo Biotech Co., Ltd.
• DRG Instruments GmbH
• Abbott Laboratories
• Snibe Diagnostic

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 336.02 million to USD 613.21 million, at a CAGR of 6.2%
Market Definition	The procalcitonin (pct) assay market encompasses all commercially relevant products and services within the defined market boundary, covering sample type, product, end-use, and related classifications.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	China, Germany, USA, South Korea, France, Italy, UK, Australia, Japan, New Zealand, 30 plus countries
Key Companies Profiled	Thermo Fisher Scientific Inc., Roche Diagnostics, bioMérieux SA, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter), Boditech Med Inc., DiaSorin S.p.A., Vazyme Biotech Co., Ltd., Sichuan Maccura Biotechnology Co., Ltd., Wondfo Biotech Co., Ltd., DRG Instruments GmbH, Abbott Laboratories, Snibe Diagnostic
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Procalcitonin (PCT) Assay Market Segmented by Sample Type:

• Serum
• Plasma
• Cell Culture Medium
• Other Biological Fluids

Procalcitonin (PCT) Assay Market Segmented by Product:

• Test Kits (Procalcitonin ELISA Test Kits, Procalcitonin CLIA Kits, PCT Immunochromatography Kits, PCT Rapid Test Kits)
• Analyzer & Instruments
• Consumables

Procalcitonin (PCT) Assay Market Segmented by End-Use:

• Hospital
• Specialty Clinics
• Academic and Research Institute
• Diagnostics Laboratories

Procalcitonin (PCT) Assay Market Segmented by Purpose:

• Clinical Use
• Research Use Only

Procalcitonin (PCT) Assay Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Bank. (2025). Global Industry Report. World Bank.
• 2. International Trade Centre. (2024). Market Analysis and Industry Review. ITC.
• 3. Organisation for Economic Co-operation and Development. (2024). OECD Industry Outlook. OECD.
• 4. United Nations Industrial Development Organization. (2025). UNIDO Industry Report. UNIDO.
• 5. International Monetary Fund. (2025). World Economic Outlook: Industry Analysis. IMF.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the size of the procalcitonin (pct) assay market and revenue projections from 2026 to 2036.
• Segmentation analysis across primary product, application, and end-user categories.
• Regional and country-level market insights covering more than 30 markets.
• Technology and methodology analysis across key operational dimensions.
• Competitive landscape assessment including company positioning and benchmarking.
• Identification of growth opportunities across segments and geographies.
• Supply chain and distribution channel tracking.
• Data delivery in PDF and Excel formats.